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Abstract
Background: Depressive symptoms have been reported to be associated with adverse clinical outcome in patients
with chronic kidney disease (CKD) not on dialysis. This association has not been examined in Europe. Anxiety and
depressive symptoms often co-occur. However, as yet there are no data concerning a possible association of anxiety
symptoms with adverse clinical outcome. We examined the association of depressive and anxiety symptoms with
adverse clinical outcome in Dutch CKD patients not on dialysis.
Methods: In this 3-year follow-up prospective cohort study, CKD patients not on dialysis with an estimated glomerular
filtration rate (eGFR)≤ 35 ml/min/1.73 m2 from an urban teaching hospital were selected. Symptoms of depression and
anxiety were evaluated using the Beck Depression Inventory (BDI) and the Beck Anxiety Inventory (BAI). Cox proportional
hazards models were used to calculate hazard ratio’s (HRs) with a composite event of death, initiation of dialysis, and
hospitalization as outcome. HRs were adjusted for age, gender, diabetes, cardiovascular disease and eGFR.
Results: Of 100 included CKD patients depressive and anxiety symptoms were present in 34 and 31 %, respectively.
Adjusted HRs for the composite event for patients with depressive and anxiety symptoms were 2.0 (95 % confidence
interval (CI) 1.2–3.5) and 1.6 (95 % CI 0.9–2.7), respectively. Twenty three patients had both depressive and anxiety
symptoms of whom adjusted HRs were 2.2 (95 % CI 1.2–4.0) for a composite event.
Conclusions: Depressive and anxiety symptoms are common in patients with CKD in The Netherlands. Depressive
symptoms are associated with an increased risk of poor clinical outcome. Anxiety symptoms show a trend for an
increased risk of poor clinical outcome. There seems to be no additive effect of anxiety symptoms in addition to
depressive symptoms with regard to poor clinical outcome.
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Background
Chronic kidney disease (CKD) is a highly prevalent
disorder that affects around 10 percent of the global
population [1]. The prevalence and incidence of renal
replacement therapy (RRT) has increased dramatically
and is predicted to further increase 29 % and 47 % re-
spectively until 2020 [2]. Despite traditional risk fac-
tors for initiation of dialysis, such as cardiovascular
disease, proteinuria, and hyperglycaemia [3, 4], there is
an increasing interest in psychosocial risk factors [5, 6],
such as depressive symptoms [7].
Depressive symptoms are common in patients with
end-stage renal disease (ESRD) [8] and associated with
mortality [9, 10]. In patients with earlier-stage CKD (stage
2–5) the prevalence of depressive symptoms is high, ran-
ging from 7 % to 42 % [11–13] and is also associated with
adverse clinical outcomes such as hospitalization, initi-
ation of dialysis, or death [7, 11, 12, 14, 15]. This associ-
ation has only been investigated in US and Asian cohorts
and not in Europe. There are important distinctions be-
tween study cohorts of CKD patients in different conti-
nents. First, the ESRD incidence is lower in in Europe,
compared to the US and Asia [16–18]. In addition, the
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relative risk for progression from CKD stages 3 or 4 to
ESRD in US white patients compared with Norwegian
patients was found to be 2.5, despite a similar CKD
prevalence [19]. Therefore, risk factors for initiation of
dialysis could vary in different continents. Secondly,
demographic differences between Europe and the US
may lead to differences in progression to ESRD [20].
Thirdly, there are differences in the health care system
between the US and Europe [20, 21].
Anxiety symptoms often co-occur with depressive
symptoms and are, in addition to depressive symp-
toms, also of interest in patients with ESRD [22]. In
this patient group anxiety symptoms are associated
with impaired health related quality of life (HRQOL),
and even seem to aggravate the relationship between
depressive symptoms and impaired HRQOL [22] . The
prevalence of anxiety symptoms varies between 13 and
50 % [22–24] in ESRD patients but the prevalence of
anxiety symptoms remains unknown in patients with
earlier-stage CKD (stage 2–5). Furthermore, it is un-
known whether anxiety symptoms are associated with
adverse clinical outcome such as death, initiation of
dialysis or hospitalization.
The aim of this study is to evaluate the prevalence of de-
pressive and anxiety symptoms in Dutch CKD patients,
and to examine the association of these symptoms with
adverse clinical outcome, defined as death, initiation of
dialysis or hospitalization. A secondary aim is to assess
the additional effect of anxiety symptoms on the associ-




All prevalent CKD patients not on dialysis in an urban
primary care hospital, the Sint Lucas Andreas Hospital
in Amsterdam the Netherlands, aged ≥18 years with an
estimated glomerular filtration rate (eGFR) of ≤ 35 ml/
min/1.73 m2 were eligible for the study. The eGFR was
calculated using the Modification of Diet in Renal
Disease (MDRD) equation [25]. Recruitment ran in the
outpatients clinic over a 3-month period from September
2011 until December 2011 and was complete when the
first hundred patients were included. Patients were
followed until 12 December 2014. Patients unable to
complete the Dutch, English, or Turkish translation of
the questionnaires, and patients who were otherwise
unable to complete the questionnaires were excluded.
The study was approved by the Medical Ethical Com-
mittee (MEC) of the Sint Lucas Andreas Hospital (ref-
erence number of the approval: mec11/115 IDO).
Informed consent was obtained from all patients prior
to enrolment.
Psychiatric assessment
Depressive symptoms were measured using the Beck
Depression Inventory (BDI) [26] and symptoms of anxiety
were measured using the Beck Anxiety Inventory (BAI)
[27]. Both questionnaires consist of 21 questions which
are scored on a 0 – 3 scale. Patients were considered to
have depressive symptoms when they scored ≥11 points
on the BDI, with a reported sensitivity and specificity of
88 and 89 %, respectively [28]. Patients were considered to
have anxiety symptoms when they scored ≥ 13 points on
the BAI with a reported sensitivity and specificity of 76
and 81 %, respectively [29, 30].
Demographic and clinical characteristics
Socio demographic, clinical and laboratory characteris-
tics were all identified from electronic medical records.
Socio demographic characteristics included age, gender,
ethnicity, marital status having children and working
status. Clinical characteristics included smoking status,
psychiatric history, present prescription of antidepres-
sants, diabetes mellitus (DM) and cardiovascular dis-
ease (previous myocardial infarction (MI), heart failure
and known coronary artery disease.
Clinical outcomes
The primary outcome was an event defined as a compos-
ite of death and initiation of dialysis treatment, or the pre-
vious two events combined with first hospitalization [7].
Secondary outcomes were the occurrence of each of these
3 events assessed separately during 3-year follow-up.
In addition eGFR was obtained from medical records
before death, initiation of dialysis, or kidney transplant-
ation. To determine the decrease in kidney function,
two eGFR values were used: one value at baseline and
one at time of follow up or just before death, initiation
of dialysis, or kidney transplantation. Decrease in kidney
function was defined as eGFR decrease in millimetres per
minute per 1.73 m2 (ml/min/1.73 m2).
Statistical analysis
Descriptive statistics and patient data listings were used
to summarize the data collected on the Case Report File.
Continuous variables were summarized using means and
standard deviations (SD). Categorical variables were de-
scribed using frequencies and percentages. Continuous
variables were compared with the use of Student’s t-test or
the Mann–Whitney U-test for skewed data. Comparison
between groups for categorical variables was performed
using the chi-square of Fisher exact test when appropriate.
Median survival time was measured using a Kaplan
Meier and median follow up with reverse Kaplan Meier
methods [31]. Patients who had a kidney transplantation,
were lost to follow up or reached the end of the study
period at December 2014 were censored. Incidence rates
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of adverse events were calculated per 1000 person-
months. Cox proportional hazard models were used to
estimate unadjusted and adjusted hazard ratios (HRs) of a
composite event (initiation of dialysis, death and first
hospitalization), a combination of death and dialysis, or
each event separately. These models were conducted for
BDI and BAI scores as dichotomized variable (presence
versus absence of depressive or anxiety symptoms) and for
BDI and BAI score as a continuous variable. Assumptions
of the proportional hazard model were confirmed by
using cumulative hazard plots. Furthermore, to deter-
mine if there is an additional effect of anxiety symp-
toms on the association of depressive symptoms and
adverse events, depressive and anxiety symptoms patients
were categorized into four groups: neither depressive or
anxiety symptoms, both depressive and anxiety symptoms,
only depressive symptoms and only anxiety symptoms.
HRs were calculated for each group with neither depres-
sive or anxiety symptoms as a reference group and all HRs
are presented with 95 % confidence intervals (CI). Age,
gender, diabetes, cardiovascular disease and eGFR were
entered in the adjusted model as covariates. These vari-
ables were based on previous reports on depressive symp-
toms and mortality among patients with CKD. Before
conducting multivariable analyses we used the variance
inflation factor (VIF) in order to control for possible mul-
ticollinearity effects. Decrease in kidney function between
low and high depressive symptoms were analysed with a
Student’s t-test. A P-value of < 0.05 (two-sided) was used
to indicate statistical significance. Statistical analysis was
performed with SPSS version 18.0.
Results
Patients characteristics
During the inclusion period, 160 CKD patients were
approached of whom 60 patients were excluded because
of motivational reasons, language barriers, or patients
were otherwise unable to fill out the questionnaires. Base-
line characteristics of 100 CKD patients with and without
depressive or anxiety symptoms are shown in Table 1.
Thirty-four patients (34 %) had depressive symptoms, de-
fined as a BDI score ≥ 11. Patients with depressive symp-
toms had more often a history of depression (p = 0.03)
and cardiovascular disease (p = 0.02). Thirty-one patients
(31 %) had anxiety symptoms, defined as a BAI score ≥ 13,
of whom more female patients (p = 0.04). There were no
further differences at baseline between patients with and
without depressive or anxiety symptoms (Table 1).
Follow up and outcomes
Median follow up was 3.1 years (minimum of 0.6, max-
imum 3.2).Seven patients lost to follow up, of whom one
patient changed to another hospital and six patients did
not show up at the outpatient clinic. Three patients had
a kidney transplantation during follow up. In total, 74
patients had a composite event (death, initiation of dialy-
sis, or hospitalization) of whom 43 patients died or were
on dialysis. Differences between patients with and with-
out depressive and anxiety symptoms are presented in
Table 2. In patients with and without depressive symp-
toms, respectively 33 and 50 % of deaths, and 16 and
17 % of hospitalizations were due to cardiovascular
disease.
Survival
The survival curves for the presence of depressive and
anxiety symptoms during 3 years of follow up showed a
higher cumulative incidence of death/dialysis or a com-
posite event for patients with depressive or anxiety
symptoms (Fig. 1). Unadjusted and adjusted (adjusted
for age, gender, history of depression, diabetes, cardiovas-
cular disease and eGFR) HRs for patients with depressive
and anxiety symptoms are presented in Table 2. Patients
with depressive symptoms had an adjusted HR of 2.1
(95%CI: 1.0 – 4.2) and 2.0 (95%CI: 1.2 – 3.5) for death/
dialysis and a composite event, respectively. Patients with
anxiety symptoms had an adjusted HR of 1.6 (95%CI: 0.8
– 3.2) and 1.6 (95%CI: 0.9 – 2.7) for death/dialysis and a
composite event, respectively. Unadjusted and adjusted
HRs for each unit increase of the BDI and BAI are pre-
sented in Table 3. Per unit increase of the BDI adjusted
HRs were 1.07 (95%CI: 1.01 – 1.13) and 1.06 (95%CI: 1.02
– 1.11) for death/dialysis and a composite event, respect-
ively. Per unit increase of the BAI adjusted HRs were 1.04
(95%CI: 1.00 – 1.09) and 1.05 (95%CI: 1.02 – 1.09) for
death/dialysis and a composite event, respectively.
Fifty eight patients had neither depressive or anxiety
symptoms, 23 had both depressive or anxiety symptoms,
11 had only depressive symptoms and 8 had only anxiety
symptoms. HRs for these four categories are presented
in Table 4. Patients with both depression and anxiety
had an adjusted HR of 2.2 (95%CI: 1.0 – 4.8) and 2.2
(95%CI: 1.2 – 4.0) for death/dialysis or a composite
event, respectively.
Kidney function
During 3-year follow up, the decrease in kidney func-
tion was 1.9 (SD 8.5) and 2.2 (SD 8.7) ml/min/1.73 m2
(p = 0.91) for patients with and without depressive
symptoms, respectively. The decrease in kidney func-
tion was 2.8 (SD 7.2) and 1.9 (SD 9.2) ml/min/1.73 m2
(p = 0.66) for patients with and without anxiety symp-
toms, respectively.
Discussion
This 3-year prospective single centre study in a cohort of
Dutch CKD patients examined the association between
depressive and anxiety symptoms with the incidence of
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adverse events defined as death, initiation of dialysis, and
hospitalization or a combination of these events. Patients
with depressive symptoms appear to have a higher risk of
progression to adverse events. Patients with anxiety symp-
toms showed a trend of progression to adverse events,
and did not seem to contribute to the association between
depressive symptoms and adverse events.
Our study showed that patients with depressive symp-
toms have a twofold higher risk of progression to death/
dialysis and a composite event (death, initiation of dialy-
sis or hospitalization). These results are comparable to
previous reported studies [7, 11, 12, 15] from primarily US
CKD cohorts. For example, Hedayati et al. [7]. found that
depression at baseline predicts progression to a composite
event of death, dialysis, or hospitalization. Despite the dif-
ferences in health care systems, lower incidence of ESRD
in Europe [16, 17, 19], and differences in patient charac-
teristics between European patients and patients from US,
the association between depressive symptoms and adverse
clinical outcome seems universally present in patients
with CKD. Furthermore, our findings demonstrate that
the presence of depressive symptoms does not influence a
decrease of kidney function. This finding is in line with a
prior study of individuals 65 years and older (Cardiovascu-
lar Health Study) [32], but not with two recent studies
that did establish a positive correlation between depressive
symptoms and a faster decrease in eGFR or progression to
dialysis [7, 12]. Difference in time of follow up, sample size
Table 1 Baseline characteristics of 100 CKD patients with and without depressive or anxiety symptoms
All patients BDI < 11 BDI≥ 11 P-value BAI < 13 BAI≥ 13 P-value
(n = 100) (n = 66) (n = 34) (n = 69) (n = 31)
Socio demographic characteristics
Age, years 67.9 (14.5) 67.8 (13.3) 67.8 (16.8) P = 0.99 68.1 (12.9) 67.3 (17.7) P = 0.81
Sex, % male 57 62 47 P = 0.15 64 42 P = 0.04
Ethnicity, % Dutch 82 83 79 P = 0.63 78 90 P = 0.15
Married or living together, % yes 58 53 71 P = 0.09 63 52 P = 0.30
Children, % yes 74 79 81 P = 0.77 78 83 P = 0.53
Employed, % yes 16 19 13 P = 0.44 18 13 P = 0.56
Clinical parameters
BMI, kg/m2 28.6 (5.5) 28.2 (5.2) 29.3 (6.1) P = 0.35 28.2 (5.3) 29.5 (5.8) P = 0.30
Current smoking, % yes 24 28 24 P = 0.69 25 30 P = 0.61
Comorbidity, % yes
Diabetes Mellitus 36 36 35 P = 0.92 35 39 P = 0.71
Hypercholesterolemia 36 38 32 P = 0.57 39 29 P = 0.33
Hypertension 76 80 68 P = 0.16 77 74 P = 0.78
Cardiovascular disease 40 32 56 P = 0.02 35 52 P = 0.11
Peripheral vascular disease 7 6 9 P = 0.61 9 3 P = 0.32
Cerebrovascular disease 14 14 15 P = 0.88 15 13 P = 0.83
COPD 9 9 9 P = 0.97 7 13 P = 0.36
History of non-skin cancer 19 18 21 P = 0.77 20 16 P = 0.62
Previous depression 7 3 15 P = 0.03 4 13 P = 0.12
Use of antidepressants, % yes 7 5 12 P = 0.18 7 7 P = 0.89
Laboratory values
Hemoglobin, g/l 7.5 (0.9) 7.5 (0.7) 7.3 (1.1) P = 0.21 7.5 (0.7) 7.4 (1.1) P = 0.51
Phophorus, mmol/l 1.35 (0.25) 1.32 (0.23) 1.41 (0.30) P = 0.14 1.34 (0.24) 1.38 (0.29) P = 0.56
Calcium, mmol/l 2.32 (0.15) 2.32 (0.16) 2.32 (0.14) P = 0.87 2.32 (0.16) 2.32 (0.14) P = 0.93
Albumin, g/l 39.9 (4.6) 39.9 (3.4) 39.9 (5.1) P = 0.99 40.2 (4.9) 38.9 (3.5) P = 0.34
Creatinine, umol/l 269 (101) 263 (80) 282 (135) P = 0.39 273 (96) 262 (114) P = 0.62
eGFR, ml/min/1,73 m2 20.4 (6.3) 20.8 (6.2) 19.8 (6.6) P = 0.49 20.3 (6.4) 20.7 (6.4) P = 0.78
Values expressed as percentage for categorical variables and mean ± standard deviation or mean (range), as appropriate
Abbreviations: COPD: chronic obstructive pulmonary disease, eGFR: estimated glomerular filtration rate
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Table 2 Association of depressive/anxiety symptoms with death, dialysis, and hospitalization in CKD patients
Events Incidence a
BDI < 11 BDI≥ 11 BDI < 11 BDI≥ 11 BDI≥ 11 BDI≥ 11
(n) (n) Unadjusted model Adjusted model b
Dialysis/Death 24 19 13.2 25.8 1.9 (1.0 – 3.5)* 2.1 (1.0 – 4.2)*
Composite event c 44 30 35.7 81.7 2.0 (1.3 – 3.3) 2.0 (1.2 – 3.5)
Death 10 9 5.5 12.2 2.2 (0.9 – 5.4) 1.5 (0.5 – 4.5)
Dialysis 14 10 7.7 13.6 1.7 (0.7 – 3.8) 2.1 (0.8 – 5.4)
Hospitalization 36 25 29.2 68.1 2.0 (1.2 – 3.4) 1.9 (1.1 – 3.5)
Events Incidence a
BAI < 13 BAI≥ 13 BAI < 13 BAI≥ 13 BAI ≥ 13 BAI≥ 13
(n) (n) Unadjusted model Adjusted model b
Dialysis/Death 28 15 15.1 21.6 1.3 (0.7 – 2.5) 1.6 (0.8 – 3.2)
Composite event c 48 26 38.5 73.8 1.7 (1.0 – 2.8)* 1.6 (0.9 – 2.7)
Death 11 8 5.9 11.5 1.6 (0.6 – 4.0) 1.5 (0.5 – 4.2)
Dialysis 17 7 9.2 10.1 1.1 (0.5 – 2.6) 1.4 (0.5 – 3.7)
Hospitalization 39 22 21.0 31.7 1.7 (0.9 – 2.9) 1.6 (0.9 – 2.8)
Values expressed as hazard ratio (95 % confidence interval)
*P < 0.05
aincidence rate of adverse events presented per 1000 person months
bAdjusted for age, gender, history of depression, diabetes, cardiovascular disease and glomerular filtration rate
cComposite event: death, initiation of dialysis or first hospitalization
Fig. 1 Kaplan-Meier survival curves for CKD patients with and without depressive or anxiety symptoms. Outcome is defined as death/dialysis or a
composite event (death, dialysis or first hospitalisation)
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or diagnostic tools to identify depressive symptoms are
possible explanations for this discrepancy.
The presence of anxiety symptoms seem to have a
trend of progression to adverse events and did not
seem to contribute to the association between depres-
sive symptoms and adverse events. This is the first
study to examine this association in CKD patients not
on dialysis. In patients with ESRD disease, however,
Preljevic et al. [22] showed that there was no additional
effect of anxiety symptoms on the relationship of de-
pressive symptoms with mortality. Although, depressive
and anxiety symptoms separately also did not have an
effect on mortality. Furthermore, our results are com-
parable to a study in patients with cardiac disease [33].
The authors concluded that anxiety was associated with
all-cause mortality, but has no additional value in case
of co-occurring depression [33]. Further research in a
larger cohort should evaluate the effect of anxiety
symptoms on adverse clinical outcome in patients with
CKD not on dialysis.
The potential mechanisms responsible for the associ-
ation of depressive symptoms with adverse clinical out-
comes are not completely clear. One plausible mechanism
is non-adherence to medical treatment. This phenomenon
was demonstrated in hemodialysis patients with depressive
symptoms who were demonstrated to be less compliant to
follow dietary and fluid restrictions or other recom-
mendations [34]. Another potential mechanism could
be that depression is associated with the activation of the
hypothalamic-pituitary-adrenal (HPA) axis and sympatho-
adrenal hyperactivity, leading to an increased release of
cortisol and catecholamine’s respectively. This may lead to
immune dysfunction, coagulation abnormalities, platelet
and vascular endothelial dysfunctions, which is linked to
increased inflammation and cardiovascular events [35–37].
A third possibility is that high depressive symptoms are
merely a surrogate marker for comorbidity such as cardio-
vascular diseases [38]. However, in our study we found a
higher prevalence of cardiovascular diseases in the pa-
tients with depressive symptoms, but after adjusting for
cardiovascular disease, the association between depressive
symptoms and poor outcomes remained the same.
This study has some limitations. First, study partici-
pants were included from a single centre with a GFR
of ≤ 35 ml. Excluded patients were not studied in a simi-
lar way as included patients. Therefore, our results may
not be applicable to other patients with other CKD
stages. Nevertheless, Hedayati et al. [7]. found a compar-
able prevalence of depression in pre-dialysis patients
with lower CKD stages Secondly, the BDI cut-off value
of 11 has been validated in pre-dialysis CKD patients
[28] whereas the BAI cut-off value of 13, which was used
in dialysis patients before [29], was validated in a general
population [30] . Therefore, the prevalence of depressive
and anxiety symptoms can differ based on the chosen
cut-off point. We do not think this influences our con-
clusion because the reported associations with adverse
events remained stable after using units increment of
Table 4 Association of depressive/anxiety categories with death, dialysis, and hospitalization in CKD patients
Neither depression or anxiety Both depression and anxiety Only depression Only anxiety
(N = 58) (N = 23) (N = 11) (N = 8)
Dialysis/death Unadjusted Reference 1.9 (0.9 – 3.9) 1.5 (0.6 – 3.8) 0.6 (0.1 – 2.6)
Dialysis/death Adjusted a Reference 2.2 (1.0 – 4.8)* 1.8 (0.6 – 4.8) 0.9 (0.2 – 4.2)
Composite event b Unadjusted Reference 2.1 (1.2 – 3.7) 2.2 (1.1 – 4.4) 1.5 (0.6 – 3.6)
Composite event b Adjusted a Reference 2.2 (1.2 – 4.0) 2.3 (1.0 – 5.3)* 1.6 (0.6 – 4.1)
Values expressed as hazard ratio (95 % confidence interval)
*P < 0.05
aAdjusted for age, gender, history of depression, diabetes, cardiovascular disease and glomerular filtration rate
bComposite event: death, initiation of dialysis or first hospitalization
Table 3 Association of depressive/anxiety symptoms (per unit increase) with death, dialysis, and hospitalisation in CKD patients
BDI/unit increase BDI/unit increase BAI/unit increase BAI/unit increase
Unadjusted Adjusted a Unadjusted Adjusted a
Dialysis/Death 1.05 (1.01 – 1.10) 1.07 (1.01 – 1.13) 1.03 (0.99 – 1.07) 1.04 (1.00 – 1.09)*
Composite event b 1.05 (1.02 – 1.09) 1.06 (1.02 – 1.11) 1.04 (1.01 – 1.08) 1.05 (1.02 – 1.09)
Death 1.07 (0.99 – 1.14) 1.04 (0.97 – 1.13) 1.03 (0.97 – 1.10) 1.01 (0.95 – 1.09)
Dialysis 1.04 (0.98 – 1.12) 1.08 (1.01 – 1.16) 1.02 (0.97 – 1.08) 1.05 (0.99 – 1.11)
Hospitalisation 1.05 (1.01 – 1.09) 1.06 (1.01 – 1.10) 1.04 (1.01 – 1.09) 1.05 (1.02 – 1.09)
Values expressed as hazard ratio (95 % confidence interval)
*P < 0.05
aAdjusted for age, gender, history of depression, diabetes, cardiovascular disease and glomerular filtration rate
bComposite event: death, initiation of dialysis or first hospitalisation
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both questionnaires. Third, we only assessed depressive
and anxiety symptoms at baseline, whereas depressive
and anxiety symptoms may change over time. However,
this will probably not influence our conclusion, because
by not using time-dependent variables the association is
most likely underestimated rather than overestimated
[39]. Future research could focus on the short term effect
of depressive and anxiety symptoms by using multiple
measurements of depressive and anxiety symptoms.
Conclusion
Depressive and anxiety symptoms are common in patients
with CKD in The Netherlands. Depressive symptoms are
associated with an increased risk of poor clinical outcome.
Anxiety symptoms show a trend for an increased risk of
poor clinical outcome. There seems to be no cumulative
effect of anxiety symptoms in addition to depressive symp-
toms. Depression and anxiety symptoms should be evalu-
ated early and future research should address appropriate
therapeutic regimens and evaluate the effect of treatment
of depression on clinical outcome.
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